23 results about "Glucose signaling" patented technology

The invention relates to a continuous blood glucose monitoring circuit, which takes a 32-bit ARM (Advanced RISC Machines) processor of an STM32F407 singlechip as a main controller and an ADS131A04 high-precision synchronous sampling ADC (Analog to Digital Converter) chip as a core, comprises a main control circuit, a signal acquisition circuit, a constant potential circuit, a constant current circuit and a power supply circuit, is connected with a blood glucose sensor by adopting an FPC (Flexible Printed Circuit) connector, and is used for continuously monitoring blood glucose under the condition of constant current stimulation and constant voltage. The output signal of the sensor is collected in real time, and after the main control processes the data, the collected data is stored in the MicroSD card and is displayed on the screen at the same time. Intelligent control over the continuous blood glucose monitoring system is achieved by means of the high running speed and rich interface resources of the STM32F407; the multi-channel design can monitor relevant ion concentration parameters while collecting blood glucose signals, and can accurately monitor the blood glucose and the relevant ion concentration of a human body and correct the blood glucose signals in cooperation with a blood glucose sensor.

The invention relates to the technical field of sensors, in particular to a CIOD-based noninvasive blood glucose detection sensor and method.The sensor comprises a multi-layer structure and comprises a first flexible polyimide substrate tightly attached to the skin, a temperature control assembly, a second flexible polyimide substrate and a glucose detection patch; the temperature control assembly comprises a temperature sensor and a heating wire and is used for thermally activating the skin; the glucose detection patch comprises three electrode areas filled with perfluorinated sulfonic acid resin, wherein the first electrode area comprises a first sodium ion working electrode, a shared electrode and a detection working electrode; the second electrode region contains a sodium ion reference electrode; the third electrode area comprises a second sodium ion working electrode and an auxiliary electrode; the electrodes are connected through insulating coating wires; the shared electrode and the auxiliary electrode form an interstitial fluid extraction electrode pair, and the detection working electrode and the shared electrode form a glucose detector to detect a hydrogen peroxide signal generated by glucose oxidation; the first sodium ion working electrode, the second sodium ion working electrode and the sodium ion reference electrode form a sodium ion differential detector to calibrate a glucose signal. According to the novel noninvasive blood glucose detection sensor provided by the invention, efficient, noninvasive and portable blood glucose monitoring can be realized by combining thermal activation and differential self-calibration.

A method for controlling glucose in a flexibly configured dual-hormone artificial pancreas, which manages optional meal and / or exercise notifications using coordinated control actions, comprising the steps of: measuring a plasma glucose signal; calculating the increase (y) of the plasma glucose measurement; defining a model for the increase in plasma glucose; defining carbohydrate intake depending on the carbohydrate content estimated by the patient; and calculating the expected postprandial increase (y) of plasma glucose depending on the administered insulin bolus. * (s) step of defining the increase in corrected plasma glucose TIFF2026529166000143.tif69, corrected insulin infusion volume TIFF2026529166000144.tif59, and adjusted carbohydrate intake Steps to define TIFF2026529166000145.tif69; control action μ r and antagonistic control action μ cr The steps include defining a virtual control action μ(s) divided into and and a nominal value prefilter F r A method comprising the step of calculating a control action using a two-degree-of-freedom (2-DOF) feedback controller having (s).

An insulin delivery device includes an insulin injection device in communication with a controller for controlling the insulin injection device. The controller is configured to receive a heart signal from one or more heart sensors, and a blood glucose signal from one or more blood glucose sensors. The controller is further configured to analyze changes in the heart rhythm of the subject based on the heart signal and determine, based on the changes in the heart rhythm and the blood glucose signal, whether the subject is and / or will be experiencing an adverse event. Upon determination that the subject is or will be experiencing an adverse event, the controller determines one or more parameters of delivery of insulin to be delivered to the subject. Finally, the controller is configured to control the injection device to deliver insulin to the subject in accordance with the determined one or more parameters of delivery.

In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time. The present invention further contemplates the extraction of one or more features of the blood glucose signal received from the one or more sensors. Using this information, a relative non-digestion- related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion- related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and / or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.

The utility model discloses a shirt capable of monitoring blood sugar, and belongs to the field of intelligent wearable equipment. The shirt comprises a shirt body, a blood glucose monitoring assembly is arranged on the shirt body, the blood glucose monitoring assembly comprises four blood glucose sensors, the four blood glucose sensors are arranged on the armpits and the back portion respectively, blood glucose signals can be accurately collected, and the blood glucose monitoring assembly is electrically connected with a microprocessor arranged on the lower hem of the back portion of the shirt and a storage battery arranged on the rear side of a collar through a flexible circuit. The flexible circuit is coated with a waterproof layer and a wear-resistant layer, the microprocessor and the storage battery are both subjected to sealing waterproof treatment, and the storage battery adopts a flexible thin film battery and is matched with a magnetic attraction contact charging mode. The waterproof flexible display screen is arranged on the cuff of the shirt, the monitoring result can be displayed in real time, the sealed waterproof NFC electronic tag is sewn at the chest portion of the inner side, and health data can be conveniently stored and read. The non-invasive, real-time and continuous blood glucose monitoring is achieved, the parts are reasonable in layout, wearing is comfortable, the protective design is durable, the functions of convenient display and data management are achieved, and powerful support is provided for health management.

The invention discloses a non-contrast agent injection tumor glucose CEST weighted imaging acquisition and post-processing method, and relates to the technical field of magnetic resonance imaging, and the method is characterized in that a 16-channel phased array coil is used on a 3.0 T MR scanner to obtain MRI; by means of the obtained MRI, a 3D glucose CEST (glucoCEST) image is obtained by means of a 3D single TSE-mDixon sequence and SPIR fat suppression; post-processing is carried out on the 3D (three-dimensional) glucoCEST image, and an MTRasym image is obtained; the change of the glucose CEST weighted signal is analyzed through MTRasym imaging, the change of the in-vivo glucose concentration is obtained, and the detection of the in-vivo glucose signal is completed. According to the magnetic resonance imaging technology based on chemical exchange saturation transfer, the contrast agent is replaced with the magnetic resonance saturation pulse for specifically inhibiting the glucose signal, in-vivo glucose signal detection can be achieved, meanwhile, the obtained image is high in resolution and low in cost, and repeated detection and clinical popularization are facilitated.

In an approach to estimating diabetes risk, the present invention receives a biomarker signal over a first period of time. From the biomarker signal, the presently claimed invention extracts one or more features of the biomarker signal and determines a first trend associated with insulin resistance based on the one or more features of the biomarker signal. Using this information, the present invention can determine a relative non-digestion-related contribution to the blood glucose signal and / or a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and / or an absolute non-digestion- related contribution is determined from the relative digestion-related and non-digestion-related contribution.

The present invention discloses a blood glucose signal processing method for blood glucose detection, which relates to the technical field of blood glucose signal processing. The method comprises: using an optical blood glucose sensor and an electrochemical blood glucose sensor to synchronously and continuously detect the blood glucose of a target user in a predicted detection window, obtaining an optical blood glucose signal detection value sequence and an electrochemical blood glucose signal detection value sequence; obtaining an optical blood glucose signal detection value subsequence set and an electrochemical blood glucose signal detection value subsequence set; performing multimodal interactive fusion analysis to obtain a blood glucose fusion feature; calling the target user's historical blood glucose feature set to authenticate the blood glucose fusion feature and obtain an authentication result. If the authentication result is passed, the blood glucose fusion feature is used as the blood glucose signal processing result. The present invention solves the technical problem in the prior art that the accuracy of blood glucose signal processing is low and it cannot effectively reflect the user's blood glucose status. The technical effect of improving the reliability of blood glucose signal processing is achieved.

A method for improving blood glucose control of a hybrid controller meal and exercise announcement by substituting patient-initiated meal boluses of said hybrid controller by an automatic insulin correction signal without retuning of said hybrid controller, and by incorporating rescue carbohydrates suggestion for hypoglycemia mitigation, comprising the steps of measuring a plasma glucose (G(t)) signal by means of a continuous glucose monitor (CGM), calculating a glucose level (Ĝ(t)) by using a glucose-insulin model; computing a disturbance term d(t), generating a virtual signal uIMC(t), for mitigating the effect of d(t) on the output, by means of an IMC filter Q(s) and converting the virtual signal uIMC(t) into three feed forward actions: insulin infusion, rescue carbohydrate suggestion, and insulin-on-board reduction.

This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.

The present invention relates to a method of controlling glucose in a flexible structure dual hormone artificial pancreas, the method managing optional meal and / or exercise alerts by means of coordinated control behavior, the method comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measure (y); defining an incremental plasma glucose model; defining carbohydrate uptake as a carbohydrate content estimated depending on the patient; defining an expected postprandial incremental plasma glucose according to the administered insulin bolus; defining a corrected incremental plasma glucose, a corrected insulin infusion, and a corrected carbohydrate uptake; defining a virtual control behavior, which is allocated between a regulatory behavior and an anti-regulatory behavior; and calculating the control behavior with a 2-DOF feedback controller having a pre-filter having a nominal value s).

Methods, devices, systems, and kits are provided that buffer the time spaced glucose signals in a memory, and when a request for real time glucose level information is detected, transmit the buffered glucose signals and real time monitored glucose level information to a remotely located device, process a subset of the received glucose signals to identify a predetermined number of consecutive glucose data points indicating an adverse condition such as an impending hypoglycemic condition, confirm the adverse condition based on comparison of the predetermined number of consecutive glucose data points to a stored glucose data profile associated with the adverse condition, where confirming the adverse condition includes generating a notification signal when the impending hypoglycemic condition is confirmed, and activate a radio frequency (RF) communication module to wirelessly transmit the generated notification signal to the remotely located device only when the notification signal is generated.

The invention provides a multi-parameter correction non-intrusive high-precision continuous blood glucose monitoring method, which is used for implementing dual real-time correction on glucose signals by synchronously detecting pH and sodium ion concentration on the surface of skin. PH correction is divided into two parts: 1, the influence of pH on the activity of glucose oxidase is compensated by utilizing an in-vitro calibration curve, so that the sensitivity of the sensor is corrected; secondly, a quantitative model of pH-Zeta potential-electroosmosis rate is established, and fluctuation of glucose extraction flux caused by skin electrical property difference is corrected. Sodium ion correction takes the assumption that the glucose / sodium ion flux ratio is equal to the tissue fluid concentration ratio as the assumption, and sodium ion flux is introduced to correct extraction flux fluctuation caused by individual differences such as skin impedance in real time. Through pH-sodium ion dual joint correction, extraction flux fluctuation and enzyme activity drift are compensated synchronously under a non-invasive condition, and continuous blood glucose monitoring with clinical precision is expected to be realized.

A system for generating a hypoglycemia risk signal associated with exercise-induced Hypoglycemia. The system can include a processor configured to obtain a blood glucose signal (BGstart), a ratio of absolute insulin on board over total daily insulin signal (IOBabs / TDI), and an initial glycemic slope signal (S0); generate a hypoglycemia risk signal based on a hypoglycemia prediction algorithm that determines the probability of a user being hypoglycemic during or after exercise based on the obtained BGstart, IOBabs / TDI and S0.

This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.

The invention provides a continuous blood glucose monitoring signal denoising method based on a two-factor layered adaptive wavelet threshold. The method comprises the following steps: firstly, performing discrete wavelet decomposition on an original noisy blood glucose signal; then, on the basis of noise characteristics of each scale, independently designing a threshold value for each layer of decomposition by adopting a hierarchical adaptive strategy; further, a novel two-factor nonlinear threshold function is introduced to perform contraction processing on the wavelet coefficient, a smooth transition factor controls function continuity near a threshold boundary to suppress a reconstruction ringing effect, and an amplitude retention factor adjusts the attenuation degree of a large-scale wavelet coefficient to retain key physiological features such as rapid change of blood glucose; and finally, reconstructing the de-noised signal through wavelet inverse transformation. According to the method, measurement noise and baseline drift are effectively suppressed, meanwhile, the fidelity capability of dynamic characteristics such as a blood glucose trend turning point is remarkably improved, and the inherent contradiction between excessive smoothness and noise residue in a traditional wavelet threshold method is relieved.

A method for controlling glucose in a flexibly structured dual-hormone artificial pancreas that manages optional meal and / or exercise notifications using coordinated control actions, which comprises: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate intake as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) depending on the insulin bolus administered; defining a corrected incremental plasma glucose y(s), a corrected insulin infusion u(s), and a corrected carbohydrate d(s) intake; defining a virtual control action µ(s), divided into regulatory actions µr and counter-regulatory actions µcr and calculating control actions using a 2-DOF feedback controller with a nominal value pre-filter Fr(s).

The application discloses a method for synchronously and efficiently metabolizing mixed sugar based on a Pichia pastoris mixed flora and application thereof. The Pichia pastoris mixed flora comprises at least one Pichia pastoris engineering strain for xylose metabolism and one Pichia pastoris engineering strain for oligosaccharide metabolism. By means of functional division of the strains, the interference of glucose signal on the xylose metabolic pathway is physically and genetically isolated, and the synchronous metabolism of xylose and cellulosic oligosaccharide is realized. The metabolic burden of each strain is reduced, the exclusive pathway of each strain can be optimized, the pathway competition and the imbalance of auxiliary factors are avoided, the overall fermentation rate and the sugar conversion rate are improved. The mixed flora system has a certain buffering capacity to environmental fluctuations and is more stable than a single strain. The strategy is particularly suitable for complex lignocellulose hydrolysate, and can effectively solve the problem of asynchronous utilization of multiple fermentable sugars in the lignocellulose hydrolysate and improve the total utilization rate of raw materials. In the process of simultaneous saccharification and fermentation of the mixed flora, the utilization rate of xylose and cellulosic oligosaccharide is improved, and the integrated biorefinery cycle is shortened.

This document discusses, among other things, systems and methods for compensating for temperature effects on sensors, such as analyte sensors. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.

In an approach to determining stress contributions to blood glucose levels, the present invention receives a blood glucose signal over a first period of time and a biomarker signal over a second period of time. The present invention extracts one or more blood glucose level signal features from the blood glucose signal, one or more biomarker signal features from the biomarker signal to determine a blood glucose level of time-based stress contribution and a biomarker-based stress contribution.

In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time and a biomarker signal from one or more sensors over an overlapping period of time. The present invention further contemplates the extraction of one or more features of the biomarker signal received from the one or more sensors. Using this information, a relative non-digestion-related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and / or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.

This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.